Broad vaccine protection against globally diverse influenza A/H5Nx viruses.

DVX-panH5Nx, a digitally immune-optimized mRNA vaccine, elicits broad HA neutralization and NA inhibition against globally diverse influenza A/H5Nx viruses, protecting mice and ferrets.

• Why it matters: H5Nx viruses diversify via reassortment across avian and mammalian hosts, and human severity varies by H5 clade and NA reassortant, making pandemic risk hard to predict.
• What they did: The team computationally engineered HA, NA, and M2 antigens spanning the global antigenic space of circulating H5Nx viruses, prioritizing N1 and N6, then tested DVX-panH5Nx in mice and ferrets.
• The result: Compared with WHO candidate vaccine viruses, DVX-panH5Nx provides superior protection against antigenically distinct H5N1 challenges spanning two decades of viral evolution, supporting scalable pre-pandemic vaccine design.

AI summary of the abstract · may contain errors · not medical advice · read the paper.